전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved158 programs
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
AntibodyLimited DatastaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#monoclonal-antibody#OncoMed
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin（RC48-ADC）)

Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Active
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-D (EB-PT-CAR-NK-D)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

EZN-2208, Cetuximab and Irinotecan (EZN-2208, Cetuximab and Irinotecan)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleMassachusetts General HospitalPhase 3

Encorafenib/Binimetinib/Cetuximab Protocol (Encorafenib/Binimetinib/Cetuximab Protocol)

Metastatic Colon Cancer; Stage III Colon Cancer · Metastatic Colon Cancer

#MetastaticColonCancer#Antibody#Phase3#monoclonal-antibody#StageIIIColonCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
AntibodyLimited DatastaleNanogen Pharmaceutical Biotechn…Phase 3

Faceptor (Faceptor)

Breast Cancer Metastatic; Breast Cancer Recurrent · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase3#monoclonal-antibody#BreastCancerRecurrent+1
Trials 1Status Active
AntibodyLimited DatastaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#monoclonal-antibody#BrightPath
Trials 1Status Discontinued
AntibodyLimited DatastaleSuzhou Kintor Pharmaceutical In…Phase 2

nivolumab (Opdivo, GT90001 and Nivolumab)

Metastatic Hepatocellular Carcinoma; HCC · Metastatic Hepatocellular Carcinoma

#MetastaticHepatocellularCarcinom#Antibody#Phase2#monoclonal-antibody#HCC+1
Trials 1Status Active
AntibodyLimited DatastaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#monoclonal-antibody#Seoul
Trials 1Status Active

5 / 8 pages

← PreviousNext →